Top Biotech Stock: Amgen’s AMG 416 Succeeds in Phase III

Amgen Inc(AMGN) shares were up 2.5% following the company’s announcement that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a randomized, double-blind, placebo-controlled 26-week long phase III study. The study evaluated the efficacy and safety of AMG 416 in 515 chronic kidney disease (CKD) patients receiving hemodialysis…

Read More
FB Nasdaq FB Facebook

DoCoMo Reports In-Line Fiscal 4Q, but Provides Lower Guidance; Under Review

NTT DoCoMo DCM reported fiscal year-end results that were generally in line with our expectations, but margin guidance for this year was lower than we anticipated. We have put our fair value estimate under review as we revise our model projections. There is no change to our economic moat rating. Revenue grew 5.4% year over…

Read More

Biotech Stock To Buy: InterMune(ITMN) Gets Breakthrough Therapy Designation

InterMune, Inc. (ITMN ) received breakthrough therapy designation for its primary product, Esbriet (pirfenidone), from the FDA. InterMune is looking to get Esbriet approved in the U.S. for the treatment of adults suffering from idiopathic pulmonary fibrosis (IPF). Breakthrough therapy designation is a status provided to candidates that show superiority over existing therapies for the…

Read More